MRNA - Oxford University Kicks off Human Study for AstraZeneca's COVID-19 Vaccine Technology in Nipah Virus Defense | Benzinga
Oxford Vaccine Group, part of the University’s Pandemic Sciences Institute, has commenced the first-in-human trial of the ChAdOx1 NipahB vaccine, targeting the deadly Nipah virus.
The trial involves 51 participants aged 18 to 55. Funded by the Coalition for Epidemic Preparedness Innovations (CEPI), this initiative marks a significant stride in combating the highly fatal Nipah virus.
The project is expected to run over the next 18 months, with further trials anticipated in a country affected by the Nipah virus.
The Nipah virus, causing fatalities in approximately 75% of cases, ...